Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan for Post-AKI Outcomes (START-or-NOT)
NCT05272878Phase 3Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney injury (AKI) comparing IRBESARTAN with Placebo (2 arms). Primary endpoint: Major Adverse Cardiovascular Events at 1 year. Started Nov 2022; status: active, not recruiting.
02
Drugs
irbesartan
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05272878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05272878.